vTv Therapeutics Inc. · NASDAQ:VTVT

vTv Therapeutics — Keystone Symposia 2016

10 slides from vTv Therapeutics's conference presentation, April 2016

  1. Slide 1: Oral Small Molecule GLP-1R Agonists for T2DM with Negligible Nausea and Vomiting

    Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting

  2. Slide 2: vTv Identified the First Oral Small Molecule Agonists of the GLP-1 Receptor in 2004

    vTv Identified the First Oral Small Molecule (allosteric) Agonists of the GLP-1 Receptor in 2004 2012 vTv’s Second Generation, TTP273, FIM Study 2008 vTv’s First Generation, 2005 TTP054, FIM Study Byetta Approved in the US 2004 Start of vTv’s Oral GLP-1R Agonist Research Program April 2016 vTv Thera

  3. Slide 3: vTv's GLP-1R Agonists Program Genesis

    vTv’s GLP-1R Agonists Program Genesis q Coordinated u1liza1on of data from cell EC50 assays, liver microsome stability, and pharmacokine1cs led to potent lead series which resulted in 2 clinical candidates TTP-595 (TTProbe™) EC50 45 µM First Genera1on Second Genera1on Series Series TTP054 TTP273 EC5

  4. Slide 4: vTv's Oral GLP-1R Agonists

    vTv's Oral GLP-1R Agonists q Novel, small, orally bioavailable molecules that ac1vate the human GLP-1R q Stand-alone allosteric GLP-1 receptor agonists q Specific for the GLP-1 receptor ØFunc1onal bias for G-protein signaling q Typical GLP1 Pharmacology in animals and humans ØEnhances insulin secre1o

  5. Slide 5: Oral Small Molecule GLP-1R Agonists with Negligible Nausea and Vomiting

    Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists with Negligible Nausea and Vomiting TTP054-108 Phase 1b T2D on MeBormin 4w TTP273-102 Phase 1b T2D on MeBormin 2w Nausea Vomi:ng Nausea Vomi:ng Placebo (n=21) 0 1 Placebo (n=29) 0 0 200QD (n=11) 1 1 25QD (n=9) 1 0 400QD (n=9) 1 1 50QD (n=9) 0 0 20

  6. Slide 6: TTP273 Shows Greater Improvement in Glycemic Control than TTP054 in Phase 1b

    TTP273 Shows Greater Improvement in Glycemic Control than TTP054 in a Phase 1b Trial q TTP273 is more efficacious than TTP054 in phase 1b at the same doses despite shorter study dura1on April 2016 vTv Therapeu1cs, LLC 6

  7. Slide 7: TTP273 Seems to Have a Better Effect on Body Weight Loss than TTP054

    TTP273 Seems to Have a Better Effect on Body Weight Loss than TTP054 in a Phase 1b Trial q No weight loss was seen in phase 1b TTP054 trial compared to placebo q TTP273 phase 1b trial showed a trend in weight loss with the BID dose regiments despite shorter study dura1on and isocaloric diet q In a 3

  8. Slide 8: Phase 2: TTP054-201 Proof of Concept

    Proof of Concept Phase 2: TTP054-201 • 3 month, randomized, double-blind, placebo-controlled, parallel group trial in 184 type 2 diabe1cs on stable doses of mecormin • 7-11.5 % baseline HbA1c • Arms: Placebo; TTP054 200mg, 400mg and 800mg QD • Primary endpoint: Change from baseline in HbA1c at 3 mon

  9. Slide 9: vTv Oral GLP1r Agonists: a Better Alternative to GLP-1 Analogue Therapy

    vTv Oral GLP1r Agonists: a Better Alternative to the GLP-1 Analogue therapy q With a superior safety and convenience profile, TTP273 could provide an alternative to current GLP-1r therapies and expand the use of this therapeutic class Effects Observed in GLP-1 vTv GLP1r Agonists Pa:ents Analogues No

  10. Slide 10: Acknowledgements

    Acknowledgements q vTv Discovery and development teams q Patricia McDonald’s lab at The Scripps Research Ins1tute, Florida April 2016 vTv Therapeu1cs, LLC 10

vTv Therapeutics — Keystone Symposia 2016 on 6ix